Helixmith Co

Helixmith Co ROE

The Return on Equity (ROE) of Helixmith Co (084990.KQ) as of Oct 22, 2026 is -0.31 %. In the previous year, Return on Equity (ROE) was -10.86 % — a change of -97.18% (higher).

ROE

-0.31 %

YoY

-97.18%

Last updated:

In 2025, Helixmith Co's return on equity (ROE) was -0.31 %, a -97.18% increase from the -10.86 % ROE in the previous year.

The Helixmith Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-21.46 KRW
Jan 1, 2019
-54.73 KRW
Jan 1, 2020
-29.99 KRW
Jan 1, 2021
-22.60 KRW
Jan 1, 2022
-20.08 KRW
Jan 1, 2023
-41.58 KRW
Jan 1, 2024
-10.86 KRW
Jan 1, 2025
-0.31 KRW
The Helixmith Co ROE history
YEARROEYoY
-0.31 %-97.18%
-10.86 %-73.88%
-41.58 %+107.04%
-20.08 %-11.16%
-22.60 %-24.62%
-29.99 %-45.21%
-54.73 %+155.04%
-21.46 %+443.32%
-3.95 %+844.97%
-0.42 %-209.30%
0.38 %+61.71%
0.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Helixmith Co's Return on Equity (ROE)

Helixmith Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Helixmith Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Helixmith Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Helixmith Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Helixmith Co stock

Return on Equity (ROE) of Helixmith Co is -0.31 % in 2025.

Return on Equity (ROE) of Helixmith Co changed from -10.86 % to -0.31 %, representing a -97.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Helixmith Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Helixmith Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Helixmith Co